The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer

Oncologist

Volumn 16, Issue 8, 2011, Pages 1154-1161

  Kim, Jin Hwi ^a   Lee, Joon Mo ^a   Ryu, Ki SungF ^a   Lee, Yong Seok ^a   Park, Yong Gyu ^a   Hur, Soo Young ^a   Lee, Keun Ho ^a   Lee, Sung Ha ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Anemia; Chemotherapy; Ovarian cancer; Prognostic factor; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; HEMOGLOBIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80052237883     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0236     Document Type: Article

References (27)

1. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst 2006;98:1655-1663.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer tatistics, 2002.CACancer J Clin 2005;55:74-108.
3. Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991;2:281-287.
4. Gershenson DM, Copeland LJ, Wharton JT et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985; 55:1129-1135.
5. Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
6. Tesarovà P, Kvasnicka J. [Treatment of anemia in patients with tumors.] Cas Lek Cesk 1995;134:647-650. In Czech.
7. Macciò A, Madeddu C, Massa D et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood 2005;106: 362-367.
8. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
9. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer:Asystemic, quantitative review. Cancer 2001;91:2214-2221.
10. Holzner B, Kemmler G, Greil R et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-973.
11. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
12. Obermair A, Handisurya A, Kaider A. et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: A prospective review. Cancer 1998;83:726-731.
13. Obermair A, Petru E, Windbichler G et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000; 7:639-644.
14. Gadducci A, Cosio S, Fanucchi A et al. Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma? Eur J Gynaecol Oncol 2003;24:405-410.
15. Münstedt K, Kovacic M, Zygmunt M et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 2003;23:837-843.
16. Gadducci A, Sartori E, Landoni F et al. Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study. Gynecol Oncol 2005;98:118-123.
17. Di Maio M, Pisano C, Tambaro R et al. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Front Biosci 2006;11:1585-1590.
18. Eichbaum MH, Weiss LM, Bruckner T et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit 2009;15:CR156-CR163.
19. Rodgers GM 3rd, Becker PS, Bennett CL et al. Cancer- and chemotherapyinduced anemia. J Natl Compr Canc Netw 2008;6:536-564.
20. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63:25-36.
21. Hyman GA. Anemia in malignant neoplastic disease. J Chronic Dis 1963; 16:645-666.
22. Spivak JL. The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 2005;5:543-555.
23. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
24. Becker A, Stadler P, Lavey RS et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-466.
25. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28(suppl 8):29-35.
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia, Version 2.2011. Available at http://www.nccn.org, accessed February 17, 2011.
27. Dy SM, Lorenz KA, Naeim A et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008;26: 3886-3895.